Impact of Cardiac Implantable Electronic Device Infection

Author:

Wilkoff Bruce L.1ORCID,Boriani Giuseppe2ORCID,Mittal Suneet3ORCID,Poole Jeanne E.4,Kennergren Charles5,Corey G. Ralph6,Love John C.7,Augostini Ralph8,Faerestrand Svein9,Wiggins Sherman S.10,Healey Jeff S.11ORCID,Holbrook Reece12ORCID,Lande Jeffrey D.12ORCID,Lexcen Daniel R.12ORCID,Willey Sarah12,Tarakji Khaldoun G.1,

Affiliation:

1. Department of Cardiovascular Medicine and Heart and Vascular Institute, Cleveland Clinic, OH (B.L.W., K.G.T.).

2. Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy (G.B.).

3. Department of Cardiology, Section of Electrophysiology, Valley Health System, Ridgewood, NJ (S.M.).

4. Department of Medicine, University of Washington School of Medicine, Seattle (J.E.P.).

5. The Sahlgrenska Academy, University of Göteborg, Sweden (C.K.).

6. Department of Medicine, Duke Clinical Research Institute, Durham, NC (G.R.C.).

7. Maine Medical Partners, Maine Medical Center, Portland (J.C.L.).

8. Department of Internal Medicine, Ohio State University, Columbus (R.A.).

9. Department of Heart Disease, University of Bergen and Haukeland University Hospital, Norway (S.F.).

10. ARK-LA-TEX Cardiology, Christus Highland Hospital, Shreveport, LA (S.S.W.).

11. Population Health Research Institute, McMaster University, ON, Canada (J.S.H.).

12. Cardiac Rhythm & Heart Failure (CRHF) Therapy Development and Clinical Research, Medtronic, Mounds View, MN (R.H., J.D.L., D.R.L., S.W.).

Abstract

Background: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. Methods: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. Results: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P <0.001), an effect that sustained beyond 12 months (hazard ratio through all follow-up, 2.30 [95% CI, 1.29–4.07]; P =0.004). Quality of life was reduced ( P =0.004) and did not normalize for 6 months. Disruptions in CIED therapy were experienced in 36% of infections for a median duration of 184 days. Mean costs were $55 547±$45 802 for the hospital, $26 867±$14 893, for medicare fee for service and $57 978±$29 431 for Medicare Advantage (mean hospital margin of −$30 828±$39 757 for medicare fee for service and −$6055±$45 033 for medicare advantage). Mean out-of-pocket costs for patients were $2156±$1999 for medicare fee for service, and $1658±$1250 for medicare advantage. Conclusions: This large, prospective analysis corroborates and extends understanding of the impact of CIED infections as seen in real-world datasets. CIED infections severely impact mortality, quality of life, healthcare utilization, and cost in the US healthcare system. Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02277990

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3